Genome-wide CRISPR screens to identify new therapeutic targets and inhibit SARS-CoV-2 replication

Key facts

Disease
COVID-19
Funder
ANR
Principal Investigator
Caroline GOUJON
Research Location
France
Lead Research Institution
Institut de Recherche en Infectiologie de Montpellier (IRIM) ? CNRS
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

The CRISPR-TARGET-CoV project, coordinated by Caroline Goujou (UMR 9004 Institut de Recherche en Infectiologie de Montpellier (IRIM) - CNRS), aims to produce screens using CRISPR technology at the genome scale in order to identify cofactors and cellular SARS-CoV-2 inhibitors. He will then focus on screening molecules of interest selected for their relevance to the cellular factors identified. The effect of the best molecules will be validated ex vivo in a 3D system of primary respiratory targets of SARS-CoV-2.

Publicationslinked via Europe PMC

Last Updated:7 hours ago

View all publications at Europe PMC

Developing injury and illness epidemiology and surveillance in cycling (PhD Academy Award).

Effects of Hand-Rearing and Group Size on Chimpanzee (Pan troglodytes) Social Competence in Captivity.

Revisiting Spirituality in Physical Therapy Practice: Perceptions of US Practitioners.

Aflibercept for Wet Age-Related Macular Degeneration: A Prospective, Randomized Trial Comparing Treat-And-Extend and Fixed Bimonthly Dosing.

The Concentration and Duration of Lipopolysaccharide Stimulation Produce Different Cytokine Responses in an Ex Vivo Whole Blood Model in Horses.

History of Shrimp Farming and the Main Viral and Bacterial Diseases in Mexico.

Identification of Risk Factors in Patients with Recurrent Cystitis May Improve Individualized Management.

ISApl4, a New IS1595 Family Insertion Sequence Forming a Novel Pseudo-Compound Transposon That Confers Antimicrobial Multidrug Resistance in Actinobacillus pleuropneumoniae.